



Benefits of involving patients and young people in paediatric clinical research

EnprEMA Annual Meeting

October 10, 2023

Steering Committee Experts

+ 50 years
of expertise in PPI

- **2006** First YPAG in the world
- **2012** Creation of eYPAGnet
- **2015** iCAN formed
- **2017** Recognition of EnprEMA
- **2018** Key partners in c4c



Jenny Preston
Senior PPI Engagement Manager,
Alder Hey Hospital, UK



Begonya Nafria
Patient Engagement in Research Coordinator
Barcelona Children's Hospital - Spain



Pamela Dicks PhD
Manager Children's Research Network
and Patient/Public Involvement Lead
NHS Scotland



Segolene Gaillard
Patient/Public Involvement Lead
Rare disease network manager
University Hospitals Lyon, France

European Network of experts in PPI

01

Professionals
embedded in
**Children's
Hospitals** and
**Clinical Research
Facilities**

02

Alongside
clinicians and
research nurses
conducting
paediatric trials in
**all paediatric
specialties**
including **rare
diseases**

03

Direct link with
**patients and
parents**
Collaboration
with **patients
associations**

04

Experience in all
clinical trials
phases,
longitudinal
studies, **non-
drug
interventions**
and **medical
device research**

European Network of experts in PPI

05

Leading experts in **developing and delivering bespoke PPI plans** that meet the needs of the client and that are consistent with eYPAGnet core values

06

Working with

- Parents and patients living with paediatric diseases
- YPAG's
- Patient Organisations
- National Paediatric Clinical Research Networks
- International Paediatric Clinical Research Networks: c4c-S
- Paediatric Hospital Services
- Paediatric Clinical Networks and Research Facilities
- Industry or academics partners

Core Values

Patients, Parents and Young
Persons Involvement is
meaningful to ALL
stakeholders

Involvement leads to change
and is **not tokenistic**

Impactful

Respectful of the needs of
the patients, parents and
young people

Core Values

Work to an agreed PPI Plan
(adapted methodology)

Inclusion of an Impact Assessment
(research, participants)

Ethical Involvement and
Engagement of Patients, Parents
and YPAGs

Standardization of activities
across countries and languages

- Best Practice Standards and Governance
- Standard CDA

eYPAGnet TODAY


Founder teams

- Generation R
- Kids France
- ScotCRN
- Kids Barcelona

**+ 30 groups
working with
young people,
patients and
parents across
Europe**

14 countries

- Belgium
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Ireland
- Italy
- Netherlands
- Poland
- Portugal
- Spain
- United Kingdom



European network of paediatric research
at the European Medicines Agency

Challenges

- ▶ Acceptability of formulation
- ▶ Clinical trial protocol:
 - ▶ Study design
 - ▶ Study endpoints relevant for Patients
 - ▶ Quality of life scales and PROMs/PREMs adapted to the disease
 - ▶ Options of digitalization and decentralization of clinical studies
 - ▶ Etc.
- ▶ Informed assent/consent documents
- ▶ Strategies of recruitment

Benefits on the ROI



50%

Time reduction for the recruitment

61 days

Time reduction of the study for one amendment, 90 days if this is a substantial amendment

535 K

Cost of one amendment per study (141.000 \$) + cost of 90 days for the approval

20%

increasing the possibility of approval by the use of study design adapted to patients

+ 25 M

Net present value

Some of our services

Study specific support

- Co-design of clinical trial protocols
- PROMS, PREMS, QoL...
- Development and review of patient documentation...
- etc...

Education and training of key stakeholders

- Co-creation (with children and families) educational resources
- Development of training for key stakeholders

PPI advice and coordination of patient and public involvement activities

- Development of patient and public involvement plans
- Execution of PPI plans

Reporting and measuring the impact of involvement

- Evaluation and impact assessments of involvement activities
- Access to co-created reporting tools

Research on PPI

+ 80 publications

Review | [Open Access](#) | [Published: 19 February 2022](#)

Developing a More Tailored Approach to Patient and Public Involvement with Children and Families in Pediatric Clinical Research: Lessons Learned

[J. Preston](#) , [B. Nafria](#), [A. Ohmer](#), [S. Gaillard](#), [P. Dicks](#), [L. West](#) & [M. A. Turner](#)

Therapeutic Innovation & Regulatory Science **56**, 948–963 (2022) | [Cite this article](#)

2667 Accesses | 1 Citations | 57 Altmetric | [Metrics](#)

Preston et al.
Research Involvement and Engagement (2023) 9:61
<https://doi.org/10.1186/s40900-023-00477-8>

Research Involvement
and Engagement

METHODOLOGY

Open Access

Reporting involvement activities with children and young people in paediatric research: a framework analysis




Jennifer Preston^{1*}, Giovanni Biglino², Victoria Harbottle^{3,4}, Emma Dalrymple⁵, Helen Stalford⁶ and Michael W. Beresford^{1,7}

Children's views on taking medicines and participating in clinical trials

Sofia Nordenmalm¹, Elin Kimland², Franca Ligas³, Birka Lehmann⁴, Joana Claverol⁵, Begonya Nafria⁵, Ann Marie Tötterman⁶, Benjamin Pelle³



Involving children and young people in clinical research through the forum of a European Young Persons' Advisory Group: needs and challenges

Segolene Gaillard , Salma Malik, Jenny Preston, Begonya Nafria Escalera, Pamela Dicks, Nathalie Touil, Sandrine Mardirossian, Joana Claverol-Torres, Behrouz Kassaï

CTS Clinical and Translational Science

ARTICLE | [Open Access](#) |    

Optimizing expert and patient input in pediatric trial design: Lessons learned and recommendations from a collaboration between connect4children and European Patient-Centric Clinical TRIAL Platforms

Britt A. E. Dhaenens , Fenna Mahler, Hannah Batchelor, Pamela Dicks, Segolene Gaillard, Begonya Nafria, Annette Kopp-Schneider, Maria Alexandra Ribeiro, Matthias Schwab ... [See all authors](#) 

First published: 30 June 2023 | <https://doi.org/10.1111/cts.13547>

Britt A. E. Dhaenens and Fenna Mahler should be considered co-first authors. Saskia N. de Wildt and Rianne Oostenbrink should be considered co-last authors.

Special Section: Pediatric Therapeutic Development: Special Section | [Published: 19 December 2019](#)

Role of Patients and Parents in Pediatric Drug Development

[Vivian W. L. Tsang](#) , [Leanne West MS](#), [Christine Woods BS](#), [Chester J. Koh MD](#), [Susan McCune MD](#), [Theresa Mullin PhD](#), [Sharon R. Smith MD](#), [Segolene Gaillard MS](#), [Joana Claverol MS](#), [Begonya Nafria MS](#), [Jennifer Preston PhD](#), [Pamela Dicks PhD](#) & [Charles Thompson MD, FCAP](#)

Therapeutic Innovation & Regulatory Science **53**, 601–608 (2019) | [Cite this article](#)

Collaboration and networking



Involving Children and Young People in the design of Paediatric Clinical Research



The future

- Continue to embed young people's involvement in clinical research
- Continue to grow the network & share best-practice
- Continue to collaborate with key stakeholders
- Continue research on PPI
- Build an evidence base on the impact of involvement
- Sustain the network through external funding

**Respecting the rights of children
and young people**

Thank you!

info@eypagnet.eu